NanoTab® Technology
AcelRx's proprietary NanoTab® technology is a non-invasive, sublingual dosage form that efficiently delivers highly lipophilic drugs with consistent pharmacokinetics. NanoTab dosage forms are designed to minimize the natural saliva response, reducing the amount of swallowed drug that results from oral transmucosal administration. Unlike sufentanil, other oral transmucosally administered drugs may be extensively absorbed through the gastrointestinal (GI) tract, leading to erratic and delayed timing to peak plasma levels.
NanoTab technology offers the following potential advantages:
- Rapid oral transmucosal absorption;
- Relatively high bioavailability via the oral mucosa and very low GI bioavailability;
- Prolonged plasma levels relative to IV delivery;
- PK parameters proportional to dose across a wide range of doses;
- Lower peak plasma concentration, or Cmax, than IV delivery; and
- Relatively low patient to patient variability in Tmax and Cmax.
